Premium
TVM Capital Healthcare, an emerging markets-focused healthcare private equity firm, has backed a Saudi Arabian bio-generic drugs manufacturing company, marking the fourth deployment from its latest Saudi-focused investment vehicle. The Dubai and Singapore-headquartered PE firm, which announced the final close of the $250-million Afiyah Fund in May, has invested $35 million ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
